1. Ferlay J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, E359-86, 2015.
2. Isobe Y., A. Nashimoto, K. Akazawa, I. Oda, K. Hayashi, I. Miyashiro, H. Katai, S. Tsujitani, Y. Kodera, Y. Seto, and M. Kaminishi, Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer, 14, 301-16, 2011.
3.厚労省,平成26年人口動態統計の年間推計, http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suikei14/dl/honbun.pdf,January 1, 2015
4. Tournigand C., T. Andre, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet, and A. de Gramont, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22, 229-37, 2004.
5. Scheithauer W., H. Rosen, G.V. Kornek, C. Sebesta, and D. Depisch, Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ, 306, 752-5, 1993.
6. Rougier P., E. Van Cutsem, E. Bajetta, N. Niederle, K. Possinger, R. Labianca, M. Navarro, R. Morant, H. Bleiberg, J. Wils, L. Awad, P. Herait, and C. Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352, 1407-12, 1998.
7. Douillard J.Y., D. Cunningham, A.D. Roth, M. Navarro, R.D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, and P. Rougier, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041-7, 2000.
8. Raymond E., S.G. Chaney, A. Taamma, and E. Cvitkovic, Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 9, 1053-71, 1998.
9. de Gramont A., A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, and A. Bonetti, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47, 2000.
10. Kidani Y., K. Inagaki, M. Iigo, A. Hoshi, and K. Kuretani, Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. J Med Chem, 21, 1315-8, 1978.
11. Mathe G., Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J.L. Misset, S. Brienza, F. de Vassals, E. Chenu, and et al., Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother, 43, 237-50, 1989.
12. Diaz-Rubio E., J. Sastre, A. Zaniboni, R. Labianca, H. Cortes-Funes, F. de Braud, C. Boni, M. Benavides, G. Dallavalle, and M. Homerin, Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol, 9, 105-8, 1998.
13. Becouarn Y., M. Ychou, M. Ducreux, C. Borel, F. Bertheault-Cvitkovic, J.F. Seitz, S. Nasca, T.D. Nguyen, B. Paillot, J.L. Raoul, J. Duffour, A. Fandi, G. Dupont-Andre, and P. Rougier, Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol, 16, 2739-44, 1998.
14. National Comprehensive Cancer Network. Clical Practice Guidelines in Oncology, Colon Cancer,version 2, 2017, https://www.nccn.org/professionals/guidelines/colon.pdf
15. National Comprehensive Cancer Network. Clical Practice Guidelines in Oncology, Rectal Cancer,version 3, 2017, https://www.nccn.org/professionals/guidelines/rectal.pdf
16. Schmoll H.J., E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, C.H. Kohne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, and A. Cervantes, ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol, 23, 2479-516, 2012.
17. 大腸癌研究会編、大腸癌治療ガイドライン医師用 2016 年版、金原出版株式 会社、2016.
18. Nordlinger B., H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, P. Rougier, W.O. Bechstein, J.N. Primrose, E.T. Walpole, M. Finch-Jones, D. Jaeck, D. Mirza, R.W. Parks, L. Collette, M. Praet, U. Bethe, E. Van Cutsem, W. Scheithauer, and T. Gruenberger, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 371, 1007-16, 2008.
19. Matsumura Y. and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46, 6387-92, 1986.
20. Hobbs S.K., W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A, 95, 4607-12, 1998.
21. Faraji A.H. and P. Wipf, Nanoparticles in cellular drug delivery. Bioorg Med Chem, 17, 2950-62, 2009.
22. Albanese A., P.S. Tang, and W.C. Chan, The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng, 14, 1-16, 2012.
23. Brannon-Peppas L. and J.O. Blanchette, Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56, 1649-59, 2004.
24. R. Gref, A. Domb, P. Quellec, T. Blunk, R.H. M¨uller, J.M. Verbavatz, and R. Langer. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev, 64, 316-26, 2012.
25. Greenwald R.B., Y.H. Choe, J. McGuire, and C.D. Conover, Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev, 55, 217-50, 2003.
26. Nishiyama N., Y. Matsumura, and K. Kataoka, Development of polymeric micelles for targeting intractable cancers. Cancer Sci, 107, 867-74, 2016.
27. Y. Kidani, K. Inagaki, R. Saito, S. Tsukagoshi, Synthesis and anti-tumor activities of platinum(II) complexes of 1,2-diaminocyclohexane isomers and their related derivatives. J Clin Hematol Oncol, 7, 197–209, 1977.
28. Kidani Y., K. Inagaki, M. Iigo, A. Hoshi, and K. Kuretani, Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. J Med Chem, 21, 1315-8, 1978.
29. Chi S.C., D.I. Yeom, S.C. Kim, and E.S. Park, A polymeric micellar carrier for the solubilization of biphenyl dimethyl dicarboxylate. Arch Pharm Res, 26, 173-81, 2003.
30. Zhang Y., T. Jin, and R.X. Zhuo, Methotrexate-loaded biodegradable polymeric micelles: preparation, physicochemical properties and in vitro drug release. Colloids Surf B Biointerfaces, 44, 104-9, 2005.
31. Choi S.W. and J.H. Kim, Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release, 122, 24-30, 2007.
32. Murakami M., H. Cabral, Y. Matsumoto, S. Wu, M.R. Kano, T. Yamori, N. Nishiyama, and K. Kataoka, Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med, 3, 64ra2, 2011.
33. Wu H., H. Cabral, K. Toh, P. Mi, Y.C. Chen, Y. Matsumoto, N. Yamada, X. Liu, H. Kinoh, Y. Miura, M.R. Kano, H. Nishihara, N. Nishiyama, and K. Kataoka, Polymeric micelles loaded with platinum anticancer drugs target preangiogenic micrometastatic niches associated with inflammation. J Control Release, 189, 1-10, 2014.
34. Cabral H., J. Makino, Y. Matsumoto, P. Mi, H. Wu, T. Nomoto, K. Toh, N. Yamada, Y. Higuchi, S. Konishi, M.R. Kano, H. Nishihara, Y. Miura, N. Nishiyama, and K. Kataoka, Systemic Targeting of Lymph Node Metastasis through the Blood Vascular System by Using Size-Controlled Nanocarriers. ACS Nano, 9, 4957-67, 2015.
35. Cabral H., N. Nishiyama, S. Okazaki, H. Koyama, and K. Kataoka, Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release, 101, 223-32, 2005.
36. Cabral H., N. Nishiyama, and K. Kataoka, Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release, 121, 146-55, 2007.
37. Cabral H., M. Murakami, H. Hojo, Y. Terada, M.R. Kano, U.I. Chung, N. Nishiyama, and K. Kataoka, Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci U S A, 110, 11397-402, 2013.
38. Quail D.F. and J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat Med, 19, 1423-37, 2013.
39. Joyce J.A., Therapeutic targeting of the tumor microenvironment. Cancer Cell, 7, 513-20, 2005.
40. Uchino H., Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, and T. Kakizoe, Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer, 93, 678-87, 2005.
41. Mantovani A., T. Schioppa, C. Porta, P. Allavena, and A. Sica, Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev, 25, 315-22, 2006.
42. Erreni M., A. Mantovani, and P. Allavena, Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron, 4, 141-54, 2011.
43. Ishida T., H. Harashima, and H. Kiwada, Liposome clearance. Biosci Rep, 22, 197-224, 2002.
44. Plummer R., R.H. Wilson, H. Calvert, A.V. Boddy, M. Griffin, J. Sludden, M.J. Tilby, M. Eatock, D.G. Pearson, C.J. Ottley, Y. Matsumura, K. Kataoka, and T. Nishiya, A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer, 104, 593-8, 2011.
45. Kato K., K. Chin, T. Yoshikawa, K. Yamaguchi, Y. Tsuji, T. Esaki, K. Sakai, M. Kimura, T. Hamaguchi, Y. Shimada, Y. Matsumura, and R. Ikeda, Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs, 30, 1621-7, 2012.
46. Takahashi A., Y. Yamamoto, M. Yasunaga, Y. Koga, J. Kuroda, M. Takigahira, M. Harada, H. Saito, T. Hayashi, Y. Kato, T. Kinoshita, N. Ohkohchi, I. Hyodo, and Y. Matsumura, NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci, 104, 920-5, 2013.